1 / 16

CMV

CMV. Patricia Wang, R1 11/15/13. Cytomegalovirus. Most common perinatal viral infection in developed countries Infects nearly 1% of all newborns Leading cause of mental retardation and sensorineural hearing loss and an important cause of cerebral palsy and retinal damage

dimaia
Télécharger la présentation

CMV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CMV Patricia Wang, R1 11/15/13

  2. Cytomegalovirus • Most common perinatal viral infection in developed countries • Infects nearly 1% of all newborns • Leading cause of mental retardation and sensorineural hearing loss and an important cause of cerebral palsy and retinal damage • Member of human herpesvirus family • Large, linear, double-stranded DNA • Infects many cell types • fibroblasts, epithelial cells, endothelial cells, macrophages, myocytes • Incubation 1-2 m

  3. Epidemiology • CMV seroprevalence is ∼50% • CMVs shed in urine for 6-40 months in younger children vs several weeks in healthy adults

  4. Risk factors • Shedding of CMV in toddlers in child care centers can be as high as 70% • Lower economic status • Immunocompromised individuals or transplant recipients with immunosuppressive therapy

  5. Transmission • Via body fluids • Ie urine, tears, saliva, genital secretions, transplanted organs • Transplacental • Infected leukocytes cross placenta in maternal viremia • Higher risk in primary maternal CMV infection (40%) • In utero transmission via genital secretions • Shedding in child care centers by toddlers with CMV (70%) • Exposure to human-infected milk, blood products, or transplanted organs • Reduce risk with pasteurized human milk, leuko-reduced blood products, and blood from CMV-negative donors

  6. Signs and symptoms of congenital CMV • 90% asymptomatic at birth • 10% symptomatic • Jaundice, heptosplenomegaly, prematurity, microcephaly, thrombocytopenia, intrauterine growth restriction, skin manifestations, poly- or oligohydramnios, pereiventricular calcifications, seizures, spasticity, developmental delay, progressive sensorineural hearling loss (30%), eye manifestations like chorioretinitis, microphthalmia, strabismus, optic nerve atrophy, and cortical visual impairment

  7. Diagnosis of mother • Symptoms • Resemble flu-like illness • Fever, pharyngitis • CDC doesn’t recommend routine maternal screening for CMV infection • No single test can rule out primary CMV infection during pregnancy

  8. Mother with primary infection • No treatment is recommended in healthy pregnant women • Vaccines for preventing CMV infection still in the research and development stage

  9. Screening • Routine testing during pregnancy not indicated • Most transplacental infections don’t result in symptomatic CMV • Most common complication (SNHL)- in infants born to mother with secondary CMV

  10. Prevention of transmission of CMV • Contact with the saliva or urine of young children- major cause of CMV infection among pregnant women. • Wash hands often with soap and water for 15-20 seconds • Follow standard handwashing procedures after contact with body fluids, such as urine and saliva, that could contain CMV • Clean surfaces that come into contact with children’s urine or saliva

  11. Diagnosis of infant • Via PCR or viral culture of CMV from urine, throat swab, or saliva • Detection within first 3 weeks for congenital CMV • Antibody titers • IgM- can be detectable when newly infected, infected in past but recent re-exposed to CMV, undergoing reactivation of CMV infection that was acquired in the past, or false-positive test • Cannot be used to diagnose congenital CMV • IgG avidity • Low-avidity IgGvs high-avidity • Not available commercially widely in US yet

  12. Evaluation and treatment of infant • No antiviral treatment approved • Phase II randomized trial with ganciclovir vs no treatment suggest benefit • Randomized to 6 weeks of IV ganciclovir or no treatment, checked hearing outcome • Toxicity of ganciclovir • Neutropenia in 65% • Evaluate ears, eyes, CNS

  13. Treatment

  14. References • CDC • Cytomegalovirus Infection Erin J. Plosa,, Jennifer C. Esbenshade, M. Paige Fuller, Joörn-Hendrik Weitkamp. Pediatrics in Review 2012; 33:156-163; doi:10.1542/pir.33-4-156 • Cytomegalovirus Infection Robert F. Pass. Pediatrics in Review 2002; 23:163-170; doi:10.1542/pir.23-5-163 • EFFECT OF GANCICLOVIR THERAPY ON HEARING IN SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS DISEASE INVOLVING THE CENTRAL NERVOUS SYSTEM: A RANDOMIZED, CONTROLLED TRIAL. J PEDIATR. 2003 JUL;143(1):16-25.

More Related